What Is FOXO4-DRI? The Senolytic Peptide Explained

Senescent cells survive partly because the protein FOXO4 holds onto p53, the cell’s “self-destruct” regulator, and keeps it in the nucleus where it stops the cell from dying.

• Blocking FOXO4–p53 binding: FOXO4-DRI mimics the part of FOXO4 that grabs p53, so it competes with the real protein and frees p53.
• Triggering cell death: freed p53 moves out of the nucleus and triggers apoptosis (programmed cell death) in the senescent cell.
• Sparing healthy cells: normal cells have little FOXO4 activity of this kind, so in lab studies they were mostly unaffected.

The 2017 Cell study. Baar et al. treated fast-aging mice and naturally old mice with FOXO4-DRI. The treated mice showed regrowth of fur, better running ability and improved kidney function, and the drug countered liver damage from chemotherapy. In cell cultures, it killed senescent cells while sparing healthy ones.

Later animal studies. A 2020 study in aged mice found FOXO4-DRI cleared senescent cells in the testes and improved testosterone production. Other lab work has looked at its effects on senescent cancer cells and lung, cartilage and kidney models.

Human data. There are no published human trials of FOXO4-DRI. A company founded by de Keizer, Cleara Biotech, has worked on next-generation FOXO4-targeting drugs, but the original peptide has not entered clinical testing.

Because FOXO4-DRI works through p53, a key tumor-suppressor and cell-death pathway, interfering with it carries theoretical risks that have not been studied in people. Senescent cells also play useful roles in wound healing and tissue repair, so removing them could have downsides. There is no human safety data, and the cost and purity of research-grade material vary widely.

No. FOXO4-DRI is not FDA-approved, has not been tested in human trials and is not on the 503A Bulks List for compounding. In the U.S. it is sold only as a research chemical labeled “not for human consumption.”

FOXO4-DRI vs dasatinib and quercetin. The D+Q combination is the most studied senolytic in people, with small pilot trials in lung fibrosis and kidney disease. FOXO4-DRI has a more targeted mechanism but no human data.

FOXO4-DRI vs epitalon. Epitalon is often grouped with longevity peptides, but it works differently, through proposed effects on telomerase and the pineal gland rather than removing senescent cells.

Products sold as FOXO4-DRI by research suppliers are laboratory chemicals, not medicines. They are not made under drug manufacturing rules, so quality varies a lot between vendors. If you are evaluating a FOXO4-DRI supplier for lab research, these are the checks that matter:

• Batch-specific COA: the certificate should match the lot number on your vial, not a generic sample.
• Independent lab: testing should come from a named third-party lab, ideally with a way to verify the report online.
• Identity, not just purity: HPLC purity alone does not confirm the right molecule; look for mass spectrometry (MS) identity confirmation.
• Endotoxin and sterility results: these matter for any injectable research material.
• Correct fill amount: the measured content should be close to the labeled milligrams.

Our Trusted Sources page lists vendors we track, with current community codes. Our guide to reading a certificate of analysis explains each line of a COA.

• FOXO4-DRI is a modified peptide that frees p53 to kill senescent cells.
• A 2017 Cell study showed improved fur, fitness and kidney function in aging mice.
• There are no human trials.
• Interfering with p53 and senescence carries theoretical risks.
• It is not FDA-approved and is sold only as a research chemical.

What is FOXO4-DRI?

FOXO4-DRI is an experimental peptide that disrupts the binding of FOXO4 and p53 in senescent cells, causing those cells to die. It is studied as an anti-aging senolytic.

Does FOXO4-DRI reverse aging?

In a 2017 mouse study it restored fur, fitness and kidney function in aging mice. It has not been tested in humans.

Is FOXO4-DRI FDA-approved?

No. It has not been tested in human trials and is sold only as a research chemical.

What does DRI mean in FOXO4-DRI?

D-retro-inverso: the peptide uses mirror-image amino acids in reverse order, which makes it resistant to breakdown in the body.

Is FOXO4-DRI safe?

There is no human safety data. Because it acts on p53 and senescence, both of which protect against cancer and support healing, there are theoretical risks.

• Baar et al. (2017), Cell – Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging
• Zhang et al. (2020), Aging – FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells
• Kirkland & Tchkonia (2020), Journal of Internal Medicine – Senolytic drugs: from discovery to translation